Genetic variants associated with longitudinal cognitive performance in older breast cancer patients and controls
Authors:
- Kelly N. H. NudelmanKNKelly N. H. Nudelman
- Kwangsik NhoKwangsik Nho
- Michael ZhangMZMichael Zhang
- Brenna C. McDonaldBrenna C. McDonald
- Wanting ZhaiWZWanting Zhai
- Brent J. SmallBSBrent J. Small
- Claire E. WegelCWClaire E. Wegel
- Paul B. JacobsenPJPaul B. Jacobsen
- Heather S. L. JimHJHeather S. L. Jim
- Sunita K. PatelSPSunita K. Patel
- Deena M. A. GrahamDGDeena M. A. Graham
- Tim A. AhlesTATim A. Ahles
Preprint
Abstract
Background: There have been no published genome-wide studies of the genetics of cancer- and treatment-related cognitive decline (CRCD); the purpose of this study is to identify genetic variants associated with CRCD in older female breast cancer survivors. Methods: Analyses included white non-Hispanic breast cancer women with non-metastatic breast cancer aged 60+ (N=325) and age-, racial/ethnic group, and education-matched controls (N=340) with pre-systemic treatment and one-year follow-up cognitive outcomes. CRCD was assessed using longitudinal domain scores on neurocognitive tests of Attention, Processing speed, and Executive function (APE), and Learning and Memory (LM). Linear regression models of one-year cognition included an interaction term for SNP or gene SNP enrichment*cancer case/control status, controlling for demographic variables and baseline cognition. Results: Cancer patients carrying minor alleles for two SNPs, rs76859653 (chromosome 1) in the hemicentin 1 ( HMCN1) gene (p=1.624×10 −8 ), and rs78786199 (chromosome 2, p=1.925×10 −8 ) in an intergenic region had lower one-year APE scores than non-carriers and controls. Gene-level analyses showed the POC5 centriolar protein gene was enriched for SNPs associated with differences in longitudinal LM performance between patients and controls. Conclusion: The SNPs associated with cognition in survivors, but not controls, were members of the cyclic nucleotide phosphodiesterase family, which play important roles in cell signaling, cancer risk, and neurodegeneration. These findings provide preliminary evidence that novel genetic loci may drive susceptibility to CRCD.Keywords
This publication has 39 references indexed in Scilit:
- KDELR2 promotes breast cancer proliferation via HDAC3‐mediated cell cycle progressionCancer Communications, 2021
- Interferon regulatory factor 8 governs myeloid cell developmentCytokine & Growth Factor Reviews, 2020
- Sleep disturbance and neurocognitive outcomes in older patients with breast cancer: Interaction with genotypeCancer, 2019
- Biological Hallmarks of Cancer in Alzheimer’s DiseaseMolecular Neurobiology, 2019
- HMCN1, a cell polarity-related gene, is somatically mutated in gastric and colorectal cancersPathology and Oncology Research, 2014
- Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: the impact of APOE and smokingPsycho-Oncology, 2014
- IRF-1 Promotes Apoptosis in p53-damaged Basal-type Human Mammary Epithelial Cells: A Model for Early Basal-type Mammary Carcinogenesis2008
- Wide Range Achievement Test 42006
- The relationship of APOE genotype to neuropsychological performance in long‐term cancer survivors treated with standard dose chemotherapyPsycho-Oncology, 2003
- “Mini-mental state”Journal of Psychiatric Research, 1975